PET/CT insights predict immunotherapy response in patients with advanced lung cancer – Health Imaging

Checkpoint inhibitors target the PD-L1/PD1 signaling pathway and are commonly used to treat those with NSCLC. While this therapy can be highly effective, it only works for nearly 50% of patients.
In order to avoid treating those who likely wont respond,…

Click here to view the original article.